Research
Hormonal
DPP4 inhibitors are effective substitutes for metformin with low hypoglycemia risk, but their cardiovascular effects are neutral and they may slightly increase heart failure risk.
DPP4 inhibitors are a good option if metformin is not tolerated, offering low hypoglycemia risk. However, they do not provide cardiovascular benefits and may have a slight risk of heart failure.
GoodQualifiesHIGH confidence
The DPP4 inhibitors have been widely used as a substitute for patients who have difficulty in using metformin monotherapy; these inhibitors are used because of their low incidence of side effects such as hypoglycemia... The effects of the DPP4 inhibitors on cardiovascular disease have been reported to be neutral... Although some DPP4 inhibitor have been reported to increase the risk of heart failure, systematic reviews have shown that the risk is not significant
Why this rating
Based on multicenter prospective randomized controlled trials and meta-analyses.
Source
Monotherapy in Patients with Type 2 Diabetes Mellitus
Sang Youl Rhee et al. · Diabetes & Metabolism Journal · 2017
DOI 10.4093/dmj.2017.41.5.349
clinical_guidelineCited 19×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Metformin is the preferred initial oral hypoglycemic agent for Type 2 Diabetes Mellitus due to its excellent blood glucose-lowering effect, relatively low side effects, long-term safety, low risk of hypoglycemia, and low weight gain.Good
- SGLT2 inhibitors reduce cardiovascular disease risk and mortality in Type 2 Diabetes patients, but are associated with increased risks of urogenital infections, dehydration, hypotension, osteoporotic fractures, and limb amputation.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →